MXPA03000434A - Compuestos de 2-piridona triciclicos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana (vih). - Google Patents

Compuestos de 2-piridona triciclicos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana (vih).

Info

Publication number
MXPA03000434A
MXPA03000434A MXPA03000434A MXPA03000434A MXPA03000434A MX PA03000434 A MXPA03000434 A MX PA03000434A MX PA03000434 A MXPA03000434 A MX PA03000434A MX PA03000434 A MXPA03000434 A MX PA03000434A MX PA03000434 A MXPA03000434 A MX PA03000434A
Authority
MX
Mexico
Prior art keywords
tricyclic
reverse transcriptase
hiv reverse
pyridone compounds
compounds useful
Prior art date
Application number
MXPA03000434A
Other languages
English (en)
Inventor
Haisheng Wang
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of MXPA03000434A publication Critical patent/MXPA03000434A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a compuestos de 2-piridona tricíclicos de la formula (I): (ver formula) o formas estereoisomérica, mezclas estereoisoméricas, o formas de sal farmacéuticamente aceptable del mismo, que son °tiles como inhibidores de la transcriptasa inversa del VIH, y a composiciones farmacéuticas y kit(s) de diagnostico que comprenden el mismo, y métodos para usar el mismo para el tratamiento de una infeccion viral o como un estándar o reactivo de ensayo.
MXPA03000434A 2000-07-20 2001-07-20 Compuestos de 2-piridona triciclicos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana (vih). MXPA03000434A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21953200P 2000-07-20 2000-07-20
US28485601P 2001-04-19 2001-04-19
PCT/US2001/022827 WO2002008226A2 (en) 2000-07-20 2001-07-20 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
MXPA03000434A true MXPA03000434A (es) 2003-06-24

Family

ID=26913986

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000434A MXPA03000434A (es) 2000-07-20 2001-07-20 Compuestos de 2-piridona triciclicos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana (vih).

Country Status (23)

Country Link
US (1) US6596729B2 (es)
EP (1) EP1303515A2 (es)
JP (1) JP2004532793A (es)
KR (1) KR20030065454A (es)
CN (1) CN1464878A (es)
AR (1) AR031861A1 (es)
AU (1) AU2001280641A1 (es)
BG (1) BG107439A (es)
BR (1) BR0112606A (es)
CA (1) CA2418194A1 (es)
EE (1) EE200300027A (es)
HU (1) HUP0302862A2 (es)
IL (1) IL153683A0 (es)
IS (1) IS6690A (es)
LT (1) LT2003003A (es)
LV (1) LV13024B (es)
MX (1) MXPA03000434A (es)
NO (1) NO20030248L (es)
PL (1) PL365958A1 (es)
SI (1) SI21139A (es)
SK (1) SK392003A3 (es)
WO (1) WO2002008226A2 (es)
YU (1) YU3203A (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
JP4822707B2 (ja) * 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 4−[[4−[[4−(2−シアノエテニル)−2,6−ジメチルフェニル]アミノ]−2−ピリミジニル]アミノ]ベンゾニトリルの製造方法
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
TW200607503A (en) 2004-05-17 2006-03-01 Tibotec Pharm Ltd 1-heterocyclyl-1, 5-dihydro-pyrido[3, 2-b]indol-2-ones

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700673A (en) * 1971-02-12 1972-10-24 Morton Norwich Products Inc 3-4-dihydrobenzo(b) (1,7)naphthyridin-1(2h)-ones
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
IL102764A0 (en) 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
AU1046895A (en) 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
DE4344452A1 (de) 1993-12-24 1995-06-29 Hoechst Ag Aza-4-iminochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung
ID18046A (id) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
ATE248826T1 (de) 1996-10-02 2003-09-15 Bristol Myers Squibb Pharma Co 4,4-disubstituierte 1,4-dihydro-2h-3,1-benzoxazin-2-one die anwendbar sind als hiv- reverstranskriptase-inhibitoren, zwischenprodukte und verfahren zu ihrer herstellung
HRP980143A2 (en) 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
US6593337B1 (en) 1999-10-19 2003-07-15 Bristol-Myers Squibb Pharma Company Tricyclic compounds useful as HIV reverse transcriptase inhibitors

Also Published As

Publication number Publication date
JP2004532793A (ja) 2004-10-28
IL153683A0 (en) 2003-07-06
YU3203A (sh) 2006-01-16
US6596729B2 (en) 2003-07-22
NO20030248L (no) 2003-03-17
HUP0302862A2 (hu) 2003-12-29
IS6690A (is) 2003-01-17
AU2001280641A1 (en) 2002-02-05
PL365958A1 (en) 2005-01-24
BG107439A (bg) 2003-09-30
WO2002008226A3 (en) 2002-06-20
KR20030065454A (ko) 2003-08-06
US20020107261A1 (en) 2002-08-08
AR031861A1 (es) 2003-10-08
CN1464878A (zh) 2003-12-31
SI21139A (sl) 2003-08-31
WO2002008226A2 (en) 2002-01-31
CA2418194A1 (en) 2002-01-31
BR0112606A (pt) 2004-06-29
EE200300027A (et) 2004-10-15
LV13024B (en) 2003-10-20
NO20030248D0 (no) 2003-01-17
EP1303515A2 (en) 2003-04-23
LT2003003A (en) 2003-11-25
SK392003A3 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
WO2001029037A3 (en) Condensed naphthyridines as hiv reverse transcriptase inhibitors
WO1998045276A3 (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
WO2001064678A3 (en) Inhibitors of hepatitis c virus ns3 protease
AU4802797A (en) 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv rever se transcriptase inhibitors and intermediates and processes for making the same
MXPA04012965A (es) Inhibidores virales.
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
ATE300541T1 (de) Pyrazolopyridinderivate
YU62504A (sh) Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
TW200710091A (en) (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
WO2004002410A3 (en) 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
MXPA03000434A (es) Compuestos de 2-piridona triciclicos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana (vih).
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
WO2005105810A3 (en) (1,10b-dihydro-2-(aminocarbonyl-phenyl)-5h-pyrazolo[1,5- c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as hiv viral replication inhibitors
SG145742A1 (en) Entry inhibitors of the hiv virus
ATE274515T1 (de) Pyrazolopyridinderivate
SE9904128D0 (sv) Novel compounds
WO2000073284A3 (en) 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
WO2004043911A3 (en) N-cycloalkylglycines as hiv protease inhibitors
WO2002078628A3 (en) Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazapines as hiv reverse transcriptase inhibitors
IL129727A0 (en) 1-(3-Aminoindazol-5-YL)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
WO2002010124A3 (en) Salt forms of an hiv protease inhibitor
TW200603782A (en) (1,10b-dihydro-2-(aminocarbonyl-phenyl)-5h-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as hiv viral replication inhibitors
TH58563B (th) สารประกอบไตรไซคลิกซึ่งเป็นประโยชน์ในฐานะสารยับยั้ง hiv รีเวอร์สทรานสคริปเทส
WO2002006190A3 (en) Crystalline and salt forms of an hiv protease inhibitor